Biosysen (HKSE:01355) Total Equity: HK$-102.90 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01355 Biosysen Ltd HKSE:01355
16 GF Score
Price HK$0.14
GF Value HK$0.06
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Biosysen Total Equity?

Biosysen HKSE:01355 -11.25% 16 Total Equity is HK$-102.90 Mil as of Dec. 2025. GuruFocus rates HKSE:01355 with a GF Score™ of 16/100 and a GF Value™ of HK$0.06 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Biosysen's total equity for the quarter that ended in Dec. 2025 was HK$-102.90 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Biosysen Total Equity Historical Data

* Premium members only.

The historical data trend for Biosysen's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosysen Total Equity Chart

Biosysen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.97 -20.87 -82.74 -105.35 -102.90

Biosysen Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -82.74 -80.30 -105.35 -83.10 -102.90
HKSE:01355
16GF Score
Biosysen Ltd HKSE:01355
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biosysen Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Biosysen's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=80.443-183.344
=-102.90

Biosysen's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=80.443-183.344
=-102.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of HK$-102.90 Mil mean?
Biosysen (HKSE:01355) has a Total Equity of HK$-102.90 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Biosysen and its competitors.
Is Biosysen's Total Equity too high?
Biosysen's current Total Equity is HK$-102.90 Mil. Overall, Biosysen has a GF Score™ of 16/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biosysen's Total Equity compare to MAR and HLT?
Biosysen's Total Equity of HK$-102.90 Mil can be compared against companies in the Travel & Leisure industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Travel & Leisure company?
A good Total Equity depends on the Travel & Leisure industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Biosysen and its competitors. Biosysen's current Total Equity is HK$-102.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosysen stock overvalued right now?
Based on GuruFocus' analysis, Biosysen (HKSE:01355) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.06, compared to a current price of HK$0.14 — trading 136.7% above its estimated fair value. The current Total Equity is HK$-102.90 Mil. Biosysen's overall GF Score™ is 16/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Biosysen (HKSE:01355), the current Total Equity is HK$-102.90 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biosysen (HKSE:01355) Overvalued in 2026?

Based on GuruFocus' analysis, Biosysen stock appears to be overvalued. The current stock price of HK$0.14 is trading 136.7% above its estimated GF Value™ of HK$0.06. GuruFocus considers Biosysen to be Significantly Overvalued.

Key valuation signals for HKSE:01355:

  • Total Equity: HK$-102.90 Mil
  • GF Value™: HK$0.06 vs. price of HK$0.14 (136.7% above fair value)
  • GF Score™: 16/100 with 9 warning signs

No single metric tells the full story. See the HKSE:01355 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biosysen Business Description

Address 28 Yun Ping Road, Level 28, Lee Garden Two, Causeway Bay, Hong Kong, HKG
Biosysen Ltd is engaged in the accommodation operations and provision of accommodation consultations and accommodation facilities management services, and other related businesses in the People's Republic of China. It has two operating segments: the Accommodation business and the Healthcare and Beauty business. It generates the majority of its revenue from the Accommodation business. Geographically, it generates all of its revenue from the PRC.
16GF Score

Get the complete analysis for HKSE:01355

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.14
Price
HK$0.06
GF Value